Estrogen and bones after menopause: a reappraisal of data and future perspectives
- 9 June 2020
- journal article
- review article
- Published by Springer Nature in Hormones
- Vol. 20 (1) , 13-21
Abstract
Menopausal hormone therapy (MHT) is effective in preventing menopause-related bone loss and decreasing vertebral, non-vertebral and hip fracture risk. MHT contains estrogens that exert both antiosteoclastic and osteoanabolic effects. These effects are dose-dependent, as even ultra-low doses preserve or increase bone mineral density. The transdermal route of administration is effective on cancellous and cortical bone, although fracture data are still lacking. Hormone replacement therapy is the treatment of choice to preserve skeletal health in women with premature ovarian insufficiency and early menopause. MHT can be considered in women aged < 60 years or within 10 years since menopause as, in this population, benefits outweigh possible risks, such as breast cancer and cardiovascular events. Despite the ensuing bone loss after MHT discontinuation, a residual antifracture effect persists. However, in women at risk of fracture, subsequent antiosteoporotic therapy may be needed, either with an antiosteoclastic or osteoanabolic agent. In any case, longitudinal data from randomized controlled trials comparing different estrogen doses and routes of administration, as well as designating the optimal treatment strategy after MHT discontinuation, are needed to elucidate these issues further.Keywords
This publication has 68 references indexed in Scilit:
- Estrogen receptor-α signaling in osteoblast progenitors stimulates cortical bone accrualJournal of Clinical Investigation, 2012
- Hip fracture in postmenopausal women after cessation of hormone therapyMenopause, 2011
- Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: Results from the Study of Women's Health Across the Nation (SWAN)Journal of Bone and Mineral Research, 2011
- Serum Sclerostin Levels Negatively Correlate with Parathyroid Hormone Levels and Free Estrogen Index in Postmenopausal WomenThe Journal of Clinical Endocrinology & Metabolism, 2010
- Runx2 Regulates G Protein-coupled Signaling Pathways to Control Growth of Osteoblast ProgenitorsJournal of Biological Chemistry, 2008
- FRAX™ and the assessment of fracture probability in men and women from the UKOsteoporosis International, 2008
- Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survivalThe EMBO Journal, 2008
- Estrogen deficiency and bone loss: an inflammatory taleJournal of Clinical Investigation, 2006
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002